Humulus Lupulus Whole

Dosage for Humulus Lupulus Whole is highly individualized and must be determined by an allergist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.

Diagnostic Dosing

• Skin Prick Test: Usually, one drop of a 1:10 or 1:20 w/v concentration is applied to the skin, followed by a prick or scratch through the drop. Results are read at 15–20 minutes.
• Intradermal Test: If the prick test is negative, 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:500 or 1:1000 w/v) may be injected into the skin.

Immunotherapy Dosing

Immunotherapy follows a 'Build-up Phase' and a 'Maintenance Phase'.

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution) administered subcutaneously once or twice weekly. The dose is gradually increased over 3 to 6 months.
• Maintenance Phase: Once the 'top dose' or 'maintenance dose' is reached (often 0.5 mL of a 1:10 or 1:20 w/v solution), injections are spaced out to every 2 to 4 weeks for a period of 3 to 5 years.

Humulus Lupulus Whole is generally considered safe for use in children, provided the child is old enough to cooperate with the testing and treatment (usually 5 years or older). Dosing logic is identical to adult dosing, though clinicians may use more conservative build-up schedules in highly sensitive children to minimize the risk of systemic reactions.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the systemic load of the protein extract is extremely low. However, if a systemic reaction occurs, the clearance of emergency medications (like certain antihistamines) might be affected.

Hepatic Impairment

No dosage adjustments are defined for hepatic impairment. The metabolism of the allergenic proteins occurs via proteolysis and is not dependent on hepatic CYP450 enzymes.

Elderly Patients

Elderly patients may have reduced skin reactivity, leading to potential false negatives in diagnostic testing. Furthermore, the risk-benefit ratio must be carefully weighed in elderly patients with significant cardiovascular disease, as they may be less able to tolerate the stress of a systemic reaction or the epinephrine used to treat it.

Humulus Lupulus Whole is never self-administered at home. It must be administered in a clinical setting.

• Preparation: The skin (usually the forearm or back) is cleaned with alcohol. For injections, the site is typically the posterior aspect of the upper arm.
• Observation: Patients MUST remain in the doctor's office for at least 30 minutes after any injection or skin test to monitor for signs of anaphylaxis.
• Storage: Extracts must be kept refrigerated at 2°C to 8°C (36°F to 46°F). Freezing must be avoided as it can denature the proteins and change the potency.

In immunotherapy, consistency is vital. If a dose is missed:

• Less than 1 week late: The usual dose may often be given.
• 1-2 weeks late: The dose may need to be held at the previous level or slightly reduced.
• More than 4 weeks late: The clinician may need to restart the build-up phase from a much lower concentration to ensure safety.

An 'overdose' in this context usually refers to an injection of a concentration higher than the patient's current tolerance level. Signs include:

• Rapid onset of hives (urticaria).
• Swelling of the throat or tongue (angioedema).
• Difficulty breathing or wheezing.
• Sudden drop in blood pressure (hypotension).
• Fainting or dizziness.

Emergency Measure: Immediate administration of intramuscular epinephrine (0.3 mg for adults) and transfer to an emergency department.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Humulus Lupulus Whole for diagnostic testing or immunotherapy will experience localized reactions. These are generally expected and indicate the immune system is responding to the allergen.

• Local Wheal and Flare: A small, itchy, raised bump at the site of the skin test or injection. This typically appears within 15 minutes and resolves within a few hours.
• Injection Site Redness (Erythema): Redness around the injection site that may feel warm to the touch. This can last for 24 to 48 hours.
• Local Pruritus (Itching): Intense itching at the site of administration. This is caused by the localized release of histamine.
• Subcutaneous Swelling: A larger area of swelling (up to the size of a half-dollar) at the injection site, which may be tender.

• Large Local Reactions (LLRs): Swelling that exceeds 5-10 cm in diameter. While not dangerous, LLRs may require a dose adjustment in future immunotherapy sessions.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Headache: Mild to moderate headache following treatment.
• Nasal Congestion: A slight increase in hay fever-like symptoms shortly after the extract is administered.

• Generalized Urticaria: Hives appearing on parts of the body far away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes, lips, or hands.
• Persistent Granuloma: A small, hard knot under the skin at the injection site that may persist for weeks.

> Warning: Stop taking Humulus Lupulus Whole and call your doctor immediately if you experience any of these symptoms of a systemic reaction.

• Anaphylaxis: A life-threatening, whole-body allergic reaction. Symptoms include a rapid, weak pulse, a skin rash, and nausea and vomiting.
• Bronchospasm: Sudden constriction of the muscles in the walls of the bronchioles, causing severe wheezing and shortness of breath.
• Laryngeal Edema: Swelling of the throat that makes it difficult to swallow or breathe.
• Hypotension: A dangerous drop in blood pressure that can lead to shock.
• Cyanosis: A bluish discoloration of the skin resulting from poor circulation or inadequate oxygenation of the blood.

With prolonged use (years of immunotherapy), the primary 'long-term' effect is the desired desensitization. However, some patients may develop a persistent sensitivity or 'priming' where they become more reactive to the injections over time rather than less. There is no evidence that Humulus Lupulus Whole causes systemic organ damage or cancer with long-term use.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Humulus Lupulus Whole allergenic extract can cause severe life-threatening systemic reactions, including anaphylaxis. This product should only be administered by healthcare professionals who are experienced in the diagnosis and treatment of allergic diseases and are equipped to manage such reactions. Patients with unstable or severe asthma are at increased risk for severe reactions. Patients must be observed for at least 30 minutes following administration. Some systemic reactions may be delayed and occur after the patient has left the clinic.

Report any unusual symptoms to your healthcare provider.

Humulus Lupulus Whole is a potent biological agent. Its use is restricted to clinical environments where emergency resuscitation equipment is available. Patients must be informed that while the extract is used to treat allergies, it is itself a concentrated form of the allergen and carries inherent risks.

No FDA black box warnings are unique to Humulus Lupulus Whole specifically, but it falls under the General Boxed Warning for Allergenic Extracts. This warning emphasizes the risk of anaphylaxis and the necessity of administration by trained personnel in facilities equipped with epinephrine and oxygen.

• Anaphylaxis Risk: The risk of a systemic reaction is higher during the build-up phase of immunotherapy or when switching to a new vial of extract, as potency can vary between lots of non-standardized products.
• Asthma Status: Patients with uncontrolled or severe asthma (FEV1 < 70% of predicted) should not receive Humulus Lupulus Whole injections, as they are at a significantly higher risk of fatal bronchospasm during a systemic reaction.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making a systemic reaction much harder to treat.
• Cardiovascular Disease: Patients with pre-existing heart conditions must be evaluated carefully, as the physiological stress of an allergic reaction or the administration of epinephrine can trigger arrhythmias or myocardial infarction (heart attack).

• Pre-Injection Assessment: Before every dose, the clinician must assess the patient for current symptoms of asthma or hay fever. If the patient is symptomatic, the dose may be delayed.
• Post-Injection Observation: A mandatory 30-minute wait time is required. The injection site and vital signs may be checked.
• Lung Function: For asthmatic patients, peak flow or spirometry may be performed before administration to ensure the airway is stable.

In the absence of a systemic reaction, Humulus Lupulus Whole does not typically affect the ability to drive. However, if a patient experiences dizziness, fatigue, or receives antihistamines/epinephrine for a reaction, they should not operate heavy machinery or drive until symptoms have fully cleared.

Alcohol consumption should be avoided for several hours before and after receiving an injection. Alcohol can increase peripheral blood flow (vasodilation), which may speed up the absorption of the allergen and increase the risk of a systemic reaction.

If a patient experiences a severe systemic reaction, the clinician will likely discontinue the immunotherapy or significantly reduce the dose. There are no 'withdrawal' symptoms associated with stopping allergenic extracts, but the patient's original allergy symptoms will likely return over time.

> Important: Discuss all your medical conditions with your healthcare provider before starting Humulus Lupulus Whole.

There are no drugs that are strictly 'contraindicated' in the sense of a chemical incompatibility, but the following should be avoided due to safety risks:

• Beta-Adrenergic Blockers: These drugs block the receptors that epinephrine acts upon. If a patient on a beta-blocker has a severe reaction to Humulus Lupulus Whole, the standard emergency treatment (epinephrine) may fail to work, leading to a potentially fatal outcome.

• ACE Inhibitors (e.g., Lisinopril): Some studies suggest that patients on ACE inhibitors may experience more frequent or more severe systemic reactions to immunotherapy, possibly due to interference with the breakdown of bradykinin.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effect of epinephrine, leading to a dangerous spike in blood pressure if emergency treatment is required.

• Antihistamines (e.g., Cetirizine, Loratadine): These drugs suppress the skin's response to histamine. If a patient takes an antihistamine before a diagnostic skin test, the result may be a 'false negative.' Patients are typically told to stop antihistamines 3 to 7 days before testing.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can alter the body's response to epinephrine.
• Systemic Corticosteroids: Long-term use of high-dose steroids may dampen the immune response to immunotherapy, potentially reducing its efficacy.

• Cross-Reactive Foods: Patients allergic to Humulus Lupulus may also react to other members of the Cannabaceae family (such as hemp or marijuana) or certain grains. Consuming these foods shortly before an injection may increase the 'allergic load' and trigger a reaction.
• High-Fat Meals: No direct interaction, but heavy meals can make the assessment of gastrointestinal symptoms of allergy (nausea/cramping) more difficult.

• Hop Supplements: Patients taking oral hop supplements for sleep or anxiety should disclose this, as this increases the total exposure to the allergen and may affect the safety of the extract injections.
• St. John's Wort: May theoretically interact with the metabolism of emergency medications, though this is not well-documented.

• Skin Tests: As mentioned, antihistamines and some sleep aids (with sedative properties) will interfere with the results.
• Total IgE Levels: Immunotherapy may cause a transient rise in total IgE levels before they eventually decline.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Conditions where Humulus Lupulus Whole must NEVER be used include:

1. 1Severe, Uncontrolled Asthma: Patients with a baseline FEV1 of less than 70% of predicted are at an unacceptable risk of fatal respiratory failure during a systemic reaction.
2. 2Recent Myocardial Infarction: If a patient has had a heart attack within the last 3-6 months, they cannot tolerate the potential cardiovascular stress of anaphylaxis or epinephrine.
3. 3History of Near-Fatal Anaphylaxis: If previous exposure to very small amounts of hops caused a life-threatening event, the risk of testing or treatment may outweigh any benefit.
4. 4Inability to Communicate: Patients who cannot describe their symptoms (e.g., severe dementia or certain neurological conditions) cannot be safely monitored during the 30-minute observation period.

• Pregnancy: While maintenance immunotherapy can often be continued, it is generally recommended NOT to start a new course of Humulus Lupulus Whole during pregnancy due to the risk of fetal hypoxia during a systemic reaction.
• Autoimmune Diseases: Patients with active systemic lupus or rheumatoid arthritis may have unpredictable immune responses.
• Acute Infection: If a patient has a fever or respiratory infection, the injection should be delayed until they are well.

Patients who are allergic to Cannabis sativa (marijuana/hemp) may show cross-sensitivity to Humulus Lupulus Whole due to shared proteins. Clinicians should exercise extra caution when testing these individuals.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Humulus Lupulus Whole.

Humulus Lupulus Whole is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not the extract itself, but the risk of a systemic reaction (anaphylaxis) in the mother. Anaphylaxis can cause a sudden drop in maternal blood pressure, leading to decreased uterine blood flow and fetal hypoxia (lack of oxygen to the baby).

• Recommendation: Do not initiate build-up therapy during pregnancy. If a patient is already on a stable maintenance dose and is tolerating it well, the clinician may choose to continue the dose or reduce it by 50% to ensure safety.

It is not known whether the protein components of Humulus Lupulus Whole are excreted in human milk. However, because these are large proteins that are likely broken down in the mother's digestive tract or local tissues, the risk to the nursing infant is considered minimal. The benefits of treating the mother's allergies usually outweigh the theoretical risks to the infant.

Humulus Lupulus Whole is used in children, but the decision must be made carefully. Children under the age of 5 may have difficulty communicating the early symptoms of a systemic reaction (such as an itchy throat or a 'sense of doom').

• Efficacy: Immunotherapy is highly effective in children and may prevent the development of asthma later in life (the 'allergic march').
• Safety: Dosing must be conservative, and the child must be able to remain still for the 30-minute observation period.

Patients over age 65 may have co-morbidities (like hypertension or heart disease) that make them poor candidates for allergenic extracts.

• Pharmacokinetics: No significant changes in how the body handles the extract, but the 'target' (the immune system) may be less responsive (immunosenescence).
• Risk: Increased risk of adverse events from epinephrine if a reaction occurs.

No dosage adjustment is necessary. The amount of protein in a 0.5 mL injection is negligible compared to the body's total protein turnover. However, clinicians should ensure the patient can clear any secondary medications used to treat reactions.

No dosage adjustment is necessary. The liver is not the primary site of clearance for these allergenic proteins.

> Important: Special populations require individualized medical assessment.

Humulus Lupulus Whole works via the IgE-mediated pathway. The extract contains specific hop allergens, such as Hum l 1 (a thaumatin-like protein).

1. 1Sensitization Phase: In allergic individuals, B-cells produce IgE antibodies specific to these hop proteins. These IgE antibodies bind to high-affinity receptors (FcεRI) on mast cells and basophils.
2. 2Effector Phase (Testing): When the extract is introduced, the hop proteins cross-link the IgE antibodies on the mast cells, triggering the release of histamine.
3. 3Desensitization Phase (Treatment): Repeated exposure via immunotherapy induces T-cell anergy and promotes the production of T-regulatory cells. These cells secrete IL-10 and TGF-beta, which signal B-cells to switch from producing IgE to producing IgG4. IgG4 acts as a 'decoy' or 'blocking antibody' that neutralizes the hop allergens before they can reach the mast cells.

• Onset of Action: Skin test reactions appear within 15–20 minutes. For immunotherapy, clinical improvement in symptoms may not be noticed for 3 to 6 months.
• Duration of Effect: A single skin test reaction lasts 2–4 hours. The effects of a full course of immunotherapy can last for several years after the treatment is stopped.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Local) |

| Protein Binding | N/A (Interacts with IgE) |

| Half-life | 1-2 hours (Proteins); Years (Immunological Memory) |

| Tmax | 15-30 minutes (Local concentration) |

| Metabolism | Local Proteolysis |

| Excretion | Renal (as amino acids/peptides) |

• Composition: A complex mixture of proteins, glycoproteins, and lipids extracted from the whole hop plant.
• Solubility: Highly soluble in buffered saline solutions.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for the various allergenic fractions.

Humulus Lupulus Whole is a Non-Standardized Allergenic Extract. It is grouped with other plant extracts like ragweed or oak, but specifically targets those with hop-related sensitivities.